Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Zaja F, Mian M, Volpetti S, Visco C, Sissa C, Nichele I, Castelli M, Ambrosetti A, Puglisi S, Fanin R, Cortelazzo S, Pizzolo G, Trentin L, Rodeghiero F, Paolini R, Vivaldi P, Sancetta R, Isola M, Semenzato G. Zaja F, et al. Among authors: sissa c. Am J Hematol. 2013 Nov;88(11):955-60. doi: 10.1002/ajh.23546. Epub 2013 Sep 9. Am J Hematol. 2013. PMID: 23861234 Free article.
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.
Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, Polverelli N, Rumi E, Caramella M, Carraro MC, D'Adda M, Molteni A, Sissa C, Lunghi F, Vismara A, Ubezio M, Guidetti A, Caberlon S, Anghilieri M, Komrokji R, Cattaneo D, Della Porta MG, Giorgino T, Bertù L, Brociner M, Kuykendall A, Passamonti F. Maffioli M, et al. Among authors: sissa c. Blood Adv. 2022 Mar 22;6(6):1855-1864. doi: 10.1182/bloodadvances.2021006889. Blood Adv. 2022. PMID: 35130339 Free PMC article.
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
Maffioli M, Giorgino T, Mora B, Iurlo A, Elli E, Finazzi MC, Caramella M, Rumi E, Carraro MC, Polverelli N, D'Adda M, Malato S, Rossi M, Molteni A, Vismara A, Sissa C, Spina F, Anghilieri M, Cattaneo D, Renso R, Bellini M, Pioltelli ML, Cavalloni C, Barraco D, Accetta R, Bertù L, Della Porta MG, Passamonti F. Maffioli M, et al. Among authors: sissa c. Blood Adv. 2019 Nov 12;3(21):3196-3200. doi: 10.1182/bloodadvances.2019000646. Blood Adv. 2019. PMID: 31698448 Free PMC article.
Dabigratan-related acute agranulocytosis.
Al-Khaffaf A, Frattini F, Sissa C, Mimiola E, Franchini M. Al-Khaffaf A, et al. Among authors: sissa c. Blood Transfus. 2019 Mar;17(2):163-164. doi: 10.2450/2019.0237-18. Epub 2019 Jan 21. Blood Transfus. 2019. PMID: 31013250 Free PMC article. No abstract available.
Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine.
Sissa C, Al-Khaffaf A, Frattini F, Gaiardoni R, Mimiola E, Montorsi P, Melara B, Amato M, Peyvandi F, Franchini M. Sissa C, et al. Transfus Apher Sci. 2021 Aug;60(4):103145. doi: 10.1016/j.transci.2021.103145. Epub 2021 Apr 16. Transfus Apher Sci. 2021. PMID: 33888416 Free PMC article. No abstract available.
Treatment of hemophilia B: focus on recombinant factor IX.
Franchini M, Frattini F, Crestani S, Sissa C, Bonfanti C. Franchini M, et al. Among authors: sissa c. Biologics. 2013;7:33-8. doi: 10.2147/BTT.S31582. Epub 2013 Feb 12. Biologics. 2013. PMID: 23430394 Free PMC article.
67 results